Japanese biotech startup Craif has raised $22 million in Series C funding to advance its AI-driven early cancer detection platform and expand into the U.S. market. Spun out from Nagoya University in 2018, Craif uses urinary microRNA biomarkers to power noninvasive cancer screening, aiming to improve early-stage detection where traditional methods fall short.
CEO Ryuichi Onose said the company now holds a valuation just under $100 million and plans to open a San Diego office alongside its existing R&D facility in Irvine, California.
Backed by investors including X&KSK and Unreasonable Group, Craif will use the new capital to expand its miSignal test, currently sold in Japan, and pursue U.S. clinical trials by 2029.
